PE/VC  RA Capital Management

     Office Locations:

20 Park Plaza, Suite 1200
Boston, MA 02116
Phone: 617-778-2500



  • Early
  • Middle Market



  • Life Sciences & Healthcare
  • Medical Device



    RA Capital Management is a crossover fund manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital to lead private, IPO, and follow-on financings for its portfolio companies, both facilitating the crossover process and allowing management teams to drive value creation with fewer capital concerns from inception through commercialization. At RA Capital's core is its TechAtlas research division, a scientifically trained team that maps out competitive landscapes in a continual effort to put data into context, identify breakthroughs, and originate conviction in new ideas. TechAtlas provides RA Capital's investment team and portfolio companies (see Beyond Capital) with strategic intelligence, market research, and other resources. The team's understanding of industry best practices is derived from an extensive collection of case studies documenting the impact of clinical trial design, partnership structures, public market dynamics, and many other factors on valuation and business viability. Additionally, RA Capital offers an Executive-in-Residence (EIR) program for experienced professionals seeking thought partners and a platform from which to survey diverse competitive landscapes in search of worthy projects.



      Fund Name



    Get funds under management for this firm including Fund name, Dollar size of fund raise, and Vintage with a National Database subscription.

    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Growth Stage
    (also called Mid-stage)
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B

    Investment Team:

    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
    Amanda Daniels COO
    Andrew Levin MD, PhD Managing Partner
    Christopher Wolf CFO
    Derek Meisner JD General Counsel & CCO
    Peter Kolchinsky PhD Founder & Managing Partner


    Recent Funding Events (trailing 12 months):







      Orchard Therapeutics



      Series C





      Series A


      TeraPore Technologies



      Series A


      Braeburn Pharmaceuticals





      Medeor Therapeutics



      Series B


    Portfolio companies include:

      Aeglea Biotherapeutics
        web link

        web link

        web link

      Braeburn Pharmaceuticals
        web link

        web link

      Dignify Therapeutics
        web link

        web link

      Kala Pharmaceuticals
        web link

      Medeor Therapeutics
        web link

      Moderna Therapeutics
        web link

      Orchard Therapeutics
        web link

      Precision BioSciences
        web link

      Ra Pharma
        web link

        web link

      Spero Therapeutics
        web link

        web link

      TARIS Biomedical
        web link

      TeraPore Technologies
        web link


    Recent News: